Who are Enteric-coated aspirin caplets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo & Aspirin, EC Aspirin 325, Placebo+ASA, Low dose ASA, Low-dose acetylsalicylic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enteric-coated-aspirin-caplets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Enteric-coated aspirin caplets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enteric-coated aspirin caplets (Enteric-coated aspirin caplets) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent / NSAID. Area: Cardiovascular.

phase 3 Antiplatelet agent / NSAID Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Enteric-coated aspirin caplets (Enteric-coated aspirin caplets) — PLx Pharma. Aspirin inhibits platelet aggregation by irreversibly acetylating cyclooxygenase (COX) enzymes, reducing thromboxane A2 production and preventing clot formation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Enteric-coated aspirin caplets TARGET	Enteric-coated aspirin caplets	PLx Pharma	phase 3	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2)
Placebo & Aspirin	Placebo & Aspirin	Baim Institute for Clinical Research	marketed	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2)
EC Aspirin 325	EC Aspirin 325	POZEN	marketed	Antiplatelet agent / NSAID	Cyclooxygenase (COX-1, COX-2)
Placebo+ASA	Placebo+ASA	Peking University Third Hospital	marketed	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1)
Low dose ASA	Low dose ASA	University of Pennsylvania	phase 3	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1)
Low-dose acetylsalicylic acid	Low-dose acetylsalicylic acid	Barcelona Institute for Global Health	phase 3	Antiplatelet agent / NSAID	Cyclooxygenase-1 (COX-1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent / NSAID class)

Baim Institute for Clinical Research · 1 drug in this class
Barcelona Institute for Global Health · 1 drug in this class
PLx Pharma · 1 drug in this class
POZEN · 1 drug in this class
Peking University Third Hospital · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enteric-coated aspirin caplets — Competitive Intelligence Brief. https://druglandscape.com/ci/enteric-coated-aspirin-caplets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing